Nerviano Medical Sciences researchers report data on a novel molecule in the Journal Clinical Cancer Research (see “NMS-E973, a Novel Synthetic Inhibitor of Hsp90 with Activity against Multiple Models of Drug Resistance to Targeted Agents, Including Intracranial Metastases”; Fogliatto, G. et al, Clin Cancer Res. 2013 Jul 1;19 (13):3520-32) .
The molecule, called NMS-E973, targets heat shock protein 90 (HSP90), a crucial player in the survival of certain cancer cells.
NMS-E973 has shown efficacy in treating preclinical tumor models, including tumors that have become resistant to molecular targeted agents. In addition, the ability of this drug to cross the so-called “blood-brain barrier”, opens up the possibility for efficacy in brain-localized disease, including metastasis occurring at this site.